Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Posterior Default Network Modulation in Alcohol Use Disorder

18. november 2026 oppdatert av: Martin Plawecki, Indiana University

This proposal will test whether repetitive transcranial magnetic stimulation (rTMS) modulation of the brain's posterior default mode network (pDMN) will alter alcohol craving, alcohol seeking and impulsivity in men and women who have an alcohol use disorder but are not seeking treatment.

Studieoversikt

Detaljert beskrivelse

Alcohol use disorder is a common medical condition affecting the lives of individuals worldwide. Many receive no treatment and relapse is high in those who do; there is a clear need for new and more effective treatments. This project will test whether the pDMN, a large-scale brain circuit most active at rest, is a potential target for therapeutic interventions.

rTMS non-invasively modulates regional cortical activity. Theta burst stimulation (TBS) is a variant of rTMS that utilizes two common patterns, continuous (cTBS) and intermittent (iTBS). This project will test the ability of cTBS and iTBS to change pDMN function, and affect alcohol seeking, alcohol craving, and impulsivity. A sham TBS treatment will be used for comparison.

Sixty participants with mild to moderate alcohol use disorder, who are not seeking treatment, will undergo baseline characterization for alcohol cue responsivity and delay discounting. They will then undergo three experimental days, in random order: (i) sham TBS, (ii) continuous (cTBS), or (iii) intermittent (iTBS). TBS will be delivered twice each experimental day. In the morning, TBS will be followed by a functional magnetic resonance imaging (fMRI) session that includes testing brain responses to alcohol and other taste cues, and delay discounting. Blood oxygenation level dependent (BOLD) contrasts will assess changes within relevant brain structures and across functional brain circuits. In the afternoon, TBS will be followed by an alcohol self-administration session during which small intravenous infusions of alcohol can be earned on a progressive ratio schedule. Number of infusions earned will be used to assess changes in alcohol motivation after TBS treatment.

Studietype

Intervensjonell

Registrering (Antatt)

70

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Ann E Kosobud, PhD
  • Telefonnummer: 3172740087
  • E-post: akosobud@iu.edu

Studer Kontakt Backup

  • Navn: James M Hays
  • Telefonnummer: 3179486550
  • E-post: haysjm@iu.edu

Studiesteder

    • Indiana
      • Indianapolis, Indiana, Forente stater, 46201
        • IU Health University Hospital
        • Hovedetterforsker:
          • Martin H Plawecki, MD, PhD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 55 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women aged 21 - 55
  • Alcohol Use Disorder diagnostic criteria based on Interview, Screening, and Measures of at least moderate severity
  • ≥7 or 14 drinks/week average over the last month or ≥ 3 or 4 drinks/occasion for women and men respectively
  • Positive alcohol cue reactivity screening
  • Systematic Delay Discounting behavior
  • Right-handed

Exclusion Criteria:

  • Physical Exam, Vital Signs, Electrocardiogram, Laboratory Values, or screening assessment precluding safe participation or experimental procedures
  • Clinical Institute Withdrawal Assessment for Alcohol (CIWA) 177 ≥8 or reported significant risk symptoms
  • MRI contraindications
  • Pregnant or breast-feeding women; Women who do not attest to using accepted forms of birth control
  • Current or desire for AUD or substance use treatment
  • Medical conditions (e.g., seizure disorder) that may influence participant safety or study outcome)
  • Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine and evidence of intoxication
  • Medications or dosage changes (past 30 days) that could influence participant safety or data (e.g., antidepressants, antipsychotics, benzodiazepines, etc.) or interact with alcohol
  • Current/history of neurological disease of cerebral origin, head injury with > 20 min loss of consciousness, medical treatment impacting MRI data, or serious psychiatric illness (bipolar disorder, psychosis).
  • Positive BrAC reading precluding visit completion
  • Actively suicidal or are at serious suicidal risk
  • Left-handed or ambidextrous
  • First degree family member with seizure disorder
  • Inability to understand English study instructions
  • Intoxication from any substance terminates an experimental day and will be considered for overall exclusion or study participation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sequence 1

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Eksperimentell: Sequence 2

On each of the three experimental study days, participants will undergo one of the following TBS treatment conditions: sham, continuous, or intermittent. Participants will receive all three treatment conditions in a randomly assigned order. To ensure participant blinding, the treatment order of this assigned sequence cannot be disclosed until the trial is concluded.

An IV alcohol self-administration session is conducted on each study day. Use of IV alcohol solutions is allowed under an FDA IND. It is a research tool and is not being tested for clinical use.

cTBS consists of a continuous train of 3-pulse bursts of neurostimulation.

iTBS consists of 2 second trains of 3-pulse bursts of neurostimulation, alternating with 8 seconds of rest.

Sham TBS duplicates the peripheral sensations of TBS without neurostimulation

Sterile alcohol is mixed with USP saline to a concentration of 6%

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in pDMN BOLD responses to alcohol taste after iTBS, cTBS or sham treatment.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

During the fMRI scan, two taste tests will be run, one alternating brief exposures to a preferred alcohol beverage and water, and a second alternating a sports drink with water. The primary comparison will be BOLD contrast [Flavor > Water] (where 'Flavor' is alcohol or sports drink) in the posterior default mode network (pDMN). Changes in response to alcohol-specific taste after iTBS, cTBS or sham treatments will be compared using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart
Change in cue-induced craving after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

In the Alcohol Cue Reactivity screen (ACR), a participant rates their current craving for alcohol before and after a 3 minute exposure to their preferred alcohol beverage in its typical glass (looking, smelling and handling the glass but not drinking). The ACR will be conducted before and after the morning TBS treatment. Change in alcohol craving after cTBS, iTBS or sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in the number of completed trials and alcohol infusions earned on a progressive ratio task after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

During the alcohol infusion session, participants will be able to earn transient increases in infusion flow rate by completing a button pressing task. Number of trials required will increase after each earned infusion. The breakpoint is defined as the number of trials completed for the last infusion earned. Breakpoints after iTBS, cTBS and sham treatments will be compared using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in impulsivity assessed using a delay discounting task after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

Delay discounting estimates impulsivity by measuring preference for immediate versus delayed rewards. To optimize the task for scanning, monetary values and starting delays will be based on an individual's performance on the task during the interview. Changes in impulsivity after cTBS, iTBS and sham treatments will be assessed using a linear or linear mixed model.

3 single day laboratory sessions scheduled 7-14 days apart
Change in pDMN BOLD responses during a delay discounting task after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

BOLD responses within the pDMN measured during the delay discounting task will be compared after cTBS, iTBS and sham treatments. Intervention (sham vs cTBS, and sham vs iTBS) and Group (sham-cTBS and sham-iTBS) contrasts will be assessed using linear or linear mixed models, controlling for age, biological sex, smoking, and subjective ratings (flavor liking and intensity, craving changes from baseline) and adjusting for multiple comparisons across regions.

3 single day laboratory sessions scheduled 7-14 days apart

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in pDMN functional connectivity during alcohol tasting after TBS treatment.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

In separate scans, brief exposures to a preferred alcohol beverage or a sports drink will be alternated with water. Functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and salience network after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

The effect of TBS treatments on functional network connectivity will be assessed by calculating changes in the correlation between pairs of nodes within the pDMN and the salience network. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in within-DMN functional connectivity during a delay discounting task after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

During the delay discounting task, functional connectivity will be estimated from regional BOLD time series using Pearson correlations. Pairwise connectivity estimates will be computed for predefined region of interest pairs within the pDMN. The difference in connectivity estimates after cTBS, iTBS and sham TBS will be assessed using linear mixed models.

3 single day laboratory sessions scheduled 7-14 days apart
Change in functional connectivity between the pDMN and cognitive control areas after TBS.
Tidsramme: 3 single day laboratory sessions scheduled 7-14 days apart

Exploratory assessments will be conducted to detect other potentially important effects of TBS on connectivity between the pDMN and cognitive control areas. Contrasts between cTBS and iTBS will be compared during delay discounting and alcohol tasting.

3 single day laboratory sessions scheduled 7-14 days apart

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Martin H Plawecki, MD, PhD, Department of Psychiatry, Indiana University School of Medicine
  • Hovedetterforsker: David Kareken, PhD, Department of Neurology, Indiana University School of Medicine

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. juni 2031

Studiet fullført (Antatt)

1. juni 2031

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

18. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

We will contribute date to the National Data Archive as required by NIH. The final raw dataset will be available to other researchers when we have collected all subjects and completed our own planned analyses. Prior to completion of our own planned analyses, we would be willing to consider releasing the dataset upon request. We will work with our IRB to establish a strategy for de-identifying the data while retaining the ability to ensure the quality of the stored data.

IPD-delingstidsramme

After all subjects have been collected and the primary outcomes accepted for publication. The dataset will be available indefinitely,

Tilgangskriterier for IPD-deling

On request to the PIs

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere